1.Off-label Medication Use of Asenapine Sublingual Tablets for Agitated Delirium in Cancer Patients at the End of Life
Hiroki NAKANO ; Naoko AKASHI ; Tomomi WADA ; Kyoko IDE ; Atsuyuki INOUE ; Takashi MIYABE ; Kazutaka YAMAUCHI
Palliative Care Research 2021;16(3):261-265
Delirium occurs in 30-40% of patients with terminal cancer, and 90% of patients are delirious immediately before death. Symptoms such as agitation and hallucination are often refractory to the standard pharmacological therapy. Also, the medication options for delirium in terminally ill patients are often limited due to a difficulty in swallowing or a lack of intravenous access. We herein report a case series of six patients with terminal cancer whose derilium symptoms were treated by asenapine sublingual tablets during the intervention period by the palliative care team. Asenapine was selected when other antipsychotics were ineffective or unavailable for agitation caused by delirium. All patients suffered dyspnea or choking sensations due to dysphagia or respiratory dysfunction. Sedative effect was observed among all patients without apparent adverse events. Sublingual asenapine could be an option for the management of restlessness due to terminal delirium when both oral and intravenous drug administration routes are not available.
2.Urinary N-terminal pro-B-type natriuretic peptide as a biomarker for cardiovascular events in a general Japanese population: the Hisayama Study.
Keisuke YAMASAKI ; Jun HATA ; Tomomi IDE ; Takuya NAGATA ; Satoko SAKATA ; Daigo YOSHIDA ; Takanori HONDA ; Yoichiro HIRAKAWA ; Toshiaki NAKANO ; Takanari KITAZONO ; Hiroyuki TSUTSUI ; Toshiharu NINOMIYA
Environmental Health and Preventive Medicine 2021;26(1):47-47
BACKGROUND:
Epidemiological evidence has shown that serum N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations, a diagnostic biomarker for heart failure, are positively associated with cardiovascular risk. Since NT-proBNP in serum is excreted in urine, it is hypothesized that urinary NT-proBNP concentrations are correlated with serum concentrations and linked with cardiovascular risk in the general population.
METHODS:
A total of 3060 community-dwelling residents aged ≥ 40 years without history of cardiovascular disease (CVD) were followed up for a median of 8.3 years (2007-2015). Serum and urinary concentrations of NT-proBNP at baseline were compared. The hazard ratios (HRs) and their 95% confidence intervals (CIs) for the association between NT-proBNP concentrations and the risk of developing CVD were computed using the Cox proportional hazards model.
RESULTS:
The median values (interquartile ranges) of serum and urinary NT-proBNP concentrations at baseline were 56 (32-104) pg/mL and 20 (18-25) pg/mL, respectively. There was a strong quadratic correlation between the serum and urinary concentrations of NT-proBNP (coefficient of determination [R
CONCLUSIONS
The present study demonstrated that urinary NT-proBNP concentrations were well-correlated with serum concentrations and were positively associated with cardiovascular risk. Given that urine sampling is noninvasive and does not require specially trained personnel, urinary NT-proBNP concentrations have the potential to be an easy and useful biomarker for detecting people at higher cardiovascular risk.
Adult
;
Aged
;
Aged, 80 and over
;
Biomarkers/urine*
;
Cardiovascular Diseases/urine*
;
Female
;
Heart Failure/diagnosis*
;
Humans
;
Incidence
;
Japan/epidemiology*
;
Male
;
Middle Aged
;
Natriuretic Peptide, Brain/urine*
;
Peptide Fragments/urine*
;
Prospective Studies
;
Risk Assessment